Early breast cancer treatment after surgery

People with early breast cancer usually get treatment after surgery, even if the surgery was successful. This is called adjuvant treatment.

After early breast cancer surgery, PERJETA is approved in combination with Herceptin® (trastuzumab) and chemotherapy for people with HER2+ early breast cancer that has a high likelihood of coming back.

Adjuvant treatment is given with curative intent to kill any cancer cells left behind after surgery, with the goal of keeping you cancer-free for as long as possible.

Keep in mind that even if you get adjuvant treatment, the cancer may still return. In addition, some people may experience serious or common side effects while receiving adjuvant treatment.

PERJETA-based therapy after surgery

You may be eligible to receive PERJETA + Herceptin-based treatment after surgery if you have HER2+ early breast cancer and:

  • You started PERJETA + Herceptin-based treatment before surgery, OR
  • Your cancer has a high chance of coming back

If you and your doctor decide that PERJETA + Herceptin-based treatment after surgery is right for you, your treatment plan might look like this:

Starting PERJETA + Herceptin-based therapy after surgery

*Unless side effects become too difficult to manage, or the cancer comes back sooner.

You should receive a total of 1 year (up to 18 cycles) of treatment with PERJETA and Herceptin. This includes any PERJETA and Herceptin you may have been given before surgery. Your treatment may be stopped sooner if your side effects become too difficult to manage or if the cancer comes back.

You will also be given chemotherapy; the dosing schedule and number of cycles will depend on which type of chemotherapy you receive. Your doctor will decide what chemotherapy regimen is right for you. Although a complete course of PERJETA + Herceptin-based therapy is a full year, chemotherapy is typically stopped sooner.

Cycle: A course of treatment that is repeated on a regular schedule with periods of rest in between. For example, PERJETA + Herceptin is given once every 3 weeks. That is one cycle.

How many cycles do I have left?

Use the information below to see how many PERJETA + Herceptin cycles you have remaining.

*Unless side effects become too difficult to manage, or the cancer comes back sooner.

This information is for reference purposes only. Please consult with your healthcare team regarding your full course of treatment. Your doctor may discontinue your treatment if side effects become too difficult to manage or if your cancer comes back.

Side effects may occur with PERJETA

What are the most serious side effects of PERJETA?

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

What are other possible serious side effects of PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA. Possible serious and sometimes fatal side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).

See additional Important Safety Information below.

How PERJETA + Herceptin-based therapy may help

PERJETA + Herceptin-based therapy after surgery has been shown to lower the risk of the cancer coming back in certain people who have HER2+ early breast cancer.

See how PERJETA + Herceptin-based therapy is given and what you may expect during your infusion.

Enroll in a free patient support program designed specifically for people living with HER2+ breast cancer.